Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia

Cancer

Volumn 109, Issue 7, 2007, Pages 1355-1359

  Aribi, Ahmed ^a   Kantarjian, Hagop M ^a   Estey, Elihu H ^a   Koller, Charles A ^a   Thomas, Deborah A ^a   Kornblau, Steven M ^a   Faderl, Stefan H ^a   Laddie, Nakia M ^a   Garcia Manero, Guillermo ^a   Cortes, Jorge E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; And molecular remission; Arsenic trioxide; Gemtuzumab ozogamycin

Indexed keywords

ARSENIC TRIOXIDE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; RETINOIC ACID;

ACUTE DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; BACTEREMIA; BILIRUBIN BLOOD LEVEL; BONE MARROW; BONE MARROW SUPPRESSION; CANCER REGRESSION; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOLLOW UP; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER VENOOCCLUSIVE DISEASE; LUNG ADENOCARCINOMA; MAINTENANCE THERAPY; METASTASIS; MORTALITY; MUCOSA INFLAMMATION; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RASH; RECURRENT CANCER; RETINOIC ACID SYNDROME; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADULT; AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXIDES; REMISSION INDUCTION; TREATMENT OUTCOME; TRETINOIN;

EID: 33947493835     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22524     Document Type: Article

References (18)

1. Collins SJ. Acute promyelocytic leukemia: relieving repression induces remission. Blood. 1998;91:2631-2633.
2. Grignani F, Fagioli M, Alcalay M, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood. 1994;83: 10-25.
3. Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol. 1990;8:1913-1921.
4. Warrell RP, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med. 1993;329:177-189.
5. Soignet S, Fleischauer A, Polyak T, Heller G, Warrell RP. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol. 1997;40(suppl):S25-S29.
6. Tallman MS. Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond. Leukemia. 1998;12(suppl 1):S37-S40.
7. Cortes JE, Kantarjian H, O'Brien S, et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer. 1994;73: 2946-2952.
8. Mandelli F, Diverio D, Awisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. The Italian Group for Malignant Hematologic Diseases in Adults and Italian Association of Hematology and Pediatric Oncology Cooperative Groups. Blood. 1997;90: 1014-1021.
9. Huang M, Ye Y, Chen S, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567-572.
10. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004;101:5328-5335.
11. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 2005;23:2396-2410.
12. Estey EH, Giles FJ, Beran M, O'Brien S. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002;99:4222-4224.
13. Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004;104:1995-1999.
14. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-4649.
15. Estey EH. Treatment options for relapsed acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16:521-534.
16. Soignet SL, Frankel SR, Douer D, et al. United States mutlicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860.
17. Dombret H, Fenaux P, Soignet SL, Tallman MS. Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol. 2002;39(2suppl 1):8-13.
18. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-1348.